Bayer HealthCare Presents Phase I Clinical Data for BAY 86-6150, a Novel Long-acting Recombinant Factor VIIa Molecule
WAYNE, N.J., July 8 Phase I clinical data for BAY86-6150, a novel recombinant factor VIIa protein (rFVIIa) being developed by Bayer HealthCare, will be presented at the XXIX International Congress of the World Federation of Hemophilia (WFH) to be held in Buenos Aires, Argentina from Saturday, July 10-Wednesday, July 14.(1)
Data to be presented are from a phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the rFVIIa variant (BAY 86-6150) in hemophilia A or B with or without inhibitors (Abstract #07P14). This study sought to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles and immunogenicity of BAY 86-6150 in non-bleeding subjects with hemophilia A or hemophilia B.
Bayer is committed to expanding scientific and clinical knowledge that improves patient care. At the Congress, Bayer will be presenting data from other globally sponsored studies and country-sponsored programs as well as hosting two satellite symposia.
For more information about Bayer HealthCare, please stop by Bayer booth #7.
About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals operation of Bayer HealthCare, an affiliate of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology, and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
BAYER and the Bayer Cross are registered trademarks of Bayer.
(1) Mahlangu J, Coetzee M, Laffan M, Windyga J, Yee T, Schroeder J. Phase I, randomized, double-blind, placebocontrolled, single-dose escalation study of the rFVIIa variant (BAY86-6150) in haemophilia A or B with or without inhibitors. Haemophilia 2010;16(Suppl. 4): Abstract 07P14. Presented at the Sunday and Monday poster sessions.
SOURCE Bayer HealthCare
You May Also Like